



## BioLineRx to Present at 2013 Annual JMP Securities Healthcare Conference in New York

July 2, 2013 11:01 AM IDT

JERUSALEM--(BUSINESS WIRE)--Jul. 2, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2013 Annual JMP Securities Healthcare Conference at the St. Regis Hotel in New York.

The BioLineRx presentation is currently scheduled to start at 4:30 p.m. EDT on Tuesday, July 9<sup>th</sup>. The presentation will be broadcast over the Internet as a "live" listen only Webcast. To listen, please go to: <http://ir.biolinerx.com/phoenix.zhtml?c=208785&p=irol-calendar>. An archive of the event will also be available for those unable to listen live.

In addition, investors attending the conference who wish to meet with Dr. Savitsky and Mr. Serlin for a one-on-one meeting should contact their JMP Securities representative.

### About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of seven clinical stage candidates: BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase 1/2 study; BL-7040 for treating inflammatory bowel disease (IBD) has completed a Phase 2a trial; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers has commenced a Phase 2 study; BL-8020 for hepatitis C (HCV) has commenced a Phase 1/2 study; BL-1021 for neuropathic pain is in Phase 1 development; and BL-1020 for schizophrenia. In addition, BioLineRx has five products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase 3) and commercialization. For more information on BioLineRx, please visit [www.biolinerx.com](http://www.biolinerx.com), the content of which does not form a part of this press release.



Source: BioLineRx

KCSA Strategic Communications  
Garth Russell / Todd Fromer  
+1 212-896-1250 / +1 212-896-1250  
[grussell@kcsa.com](mailto:grussell@kcsa.com) / [tfromer@kcsa.com](mailto:tfromer@kcsa.com)

or  
BioLineRx  
Tsipi Haitovsky  
Public Relations  
+972-3-6240871  
[tsipih@netvision.net.il](mailto:tsipih@netvision.net.il)